



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 27-10-2008

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 18-10-2008 TO BE PUBLISHED 28-10-2008 IN THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
**Karachi**

No.2/2/2003-F.Sec.

Dated: 27-10-2008

To,

Mr. Manzoor Ahmed  
Section Officer  
Cabinet Secretariat  
Cabinet Division  
Government of Pakistan  
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 18-10-2008 TO BE PUBLISHED 28-10-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23<sup>rd</sup> April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1194/2008	<b><u>13-10-2008</u></b> Honda Motor Co. Ltd, Japan (Priority 17-10-07 Japan)	“Front vehicle body structure”
1195/2008	Glaxo Group Limited, Great Britain (Priority 15-11-05 USA) <b>Divisional</b>	“Substituted dihyropyrido[2,3-d]pyrimidine-6-carboxylic acid compound”
1196/2008	Syngenta Participations AG, Switzerland (Priority 15-7-07 UK)	“Chemical compounds”
1197/2008	<b><u>14-10-2008</u></b> Janssen Pharmaceutica N.V., Belgium (Priority 18-10-2007 USA)	“Improved process for preparing 2-(substituted phenyl) ?2 hydroxy-ethyl carbamates”
1198/2008	Janssen Pharmaceutica N.V., Belgium (Priority 17-10-2007 USA)	“Inhibitors pf c-fms kinase”
1199/2008	Sanofi Aventis France (Priority 15-10-07 Europe)	“Antibodies that bind IL-4 and /or IL-13and their uses”
1200/2008	Glaxo Group Limited, United Kingdom (Priority 16-10-07 USA)	“Pharmaceutical compositions”
1201/2008	Wyeth, USA (Priority 16-10-07 USA)	“Tigecycline and methods of preparing intermediates”
1202/2008	<b><u>15-10-2008</u></b> Wyeth, USA (Priority 17-10-07 USA)	“Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy ) aniline]-3-cyano-7-ethoxy-6-quinoliny]}-4-(dimethylamino)-2-butenamide, crystalline forms thereof, processes for their preparation, and

		methods for their use”
1203/2008	Wyeth, USA (Priority 16-10-07 USA)	“Thienopyrimidine pyrazolopyrimidine compounds and their use as mtor kinase and PI3 kinase inhibitors”
1204/2008	1.Shahzad Alam, 2.Farzana Habib 3.Muhammad Irfan 5.Kanwal Mahmood and 6.Dr. Tariq Sohail PCSIR, Karach.	“ A process for the development of hydroxyapatite from eggshells”
1205/2008	1.Lubna Iqbal 2.Mr. Muhammad Saleem 3.Mehreen Lateef PCSIR, Karachi	“A process for the preparation of lactase free milk supplement for lactose intolerant population”
1206/2008	MGI Pharma Inc. USA (Priority 16-10-07 USA)	“Certain compounds compositions and methods”
1207/2008	Janssen Pharmaceutica N.V. Belgium (Priority 16-10-07 USA)	“Process for synthesizing phosphonic and phosphinic acid compounds”
1208/2008	Novartis Ag, Switzerland (Priority 17-10-07 Europe)	“Organic compounds”
1209/2008	Invista Technologies S.a r.l. Switzerland (Priority 17-10-07 USA)	“Preparation of very high molecular weight polyamide filaments”
1210/2008	1.ENI S.p.A Italy 2.IFP, France (Priority 18-10-07 France)	“Device for separating a finely divided solid in suspension in a viscous liquid”
1211/2008	Novartis AG, Switzerland (Priority 17-10-07 Europe)	“Organic compounds”

1212/2008	Novartis AG, Switzerland (Priority 16-10-07 Europe)	“Organic compounds”
1213/2008	Novartis AG, Switzerland (Priority 16-10-07 Europe)	“Organic compounds”
1214/2008	Novartis AG, Switzerland (Priority 16-10-07 Europe)	“Organic compounds”
	<b><u>16-10-2008</u></b>	
1215/2008	AstraZeneca AB, Sweden (Priority 19-10-07 USA)	“New compounds 067”
1216/2008	Janssen Pharmaceutica N.V., Belgium (Priority 18-10-07 Europe)	“Trisubstituted 1,2,4 triazoles”
1217/2008	Janssen Pharmaceutica N.V., Belgium (Priority 18-10-07 Europe)	“ 1, 3, 5-Trisubstituted triazole derivative”
1218/2008	Atlas Elektronik GmbH, Germany (Priority 29-10-07 Germany)	“Apparatus AMD method for generating a stereo audio signal”
1219/2008	Schering Corporation, USA (Priority 19-10-07 USA)	“Compounds for inhibiting KSP kinesin activity”
1220/2008	Schering Corporation, USA (Priority 19-11-07 USA)	“Compounds for inhibiting KSP kinesin activity”
1221/2008	Sanofi-Aventis France (Priority 22-9-06 France) <b>Divisional</b>	“An acid addition salt and/or solvate of a substituted octahydroindolizine compounds”
1222/2008	1. Labopharm Inc.	“Bilayer composition for the controlled

	Canada 2. Labopharm Europe Limited, Ireland 3. Labopharm (Barbados) Limited Barbados (Priority 16-10-07 USA)	release of acetaminophen and tramadol”
1223/2008	LT COL (R ) Muhammad Shah Lahore, Pakistan	“Solid fuel stove”
	<b><u>17-10-2008</u></b>	
1224/2008	Paion Deutschland GmbH Germany (Priority 18-10-07 Europe)	“Novel patient subgroups for thrombolysis”
1225/2008	Porous Media Corporation USA (priority 20-10-07 USA)	“Method and apparatus for the purification of salty streams and the removal of particulates therefrom”
1226/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 31-8-05 Japan) <b>Divisional</b>	“A slat of a substituted benzo [ b ] thiophen compound”
1227/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 19-10-07 Japan)	“Pharmaceutical solid preparation”
1228/2008	Sanofi-Aventis France (Priority 19-10-07 France)	“Novel derivatives of 6-aryl/heteroalkyloxy benzothiazole and benzimidazole, their method of preparation, their application as medicinal products, pharmaceutical compositions and novel use notably as c-met inhibitors”
1229/2008	1. Elan Pharma International Limited, Ireland 2. Wyeth, USA	“Immunotherapy regimes dependent on apoe status”

(Priority 17-10-07 USA)

1230/2008	Boehringer Ingelheim International GmbH, Germany (Priority 19-10-07 Europe)	“Substituted piperidino- dihydrothienopyrimidines”
1231/2008	Boehringer Ingelheim International GmbH, Germany (Priority 19-10-07 Europe)	“Heterocycle substituted piperazino dihydrothienopyrimidines”
1232/2008	Reckitt Benckiser HealthCare (UK) Limited United Kingdom (Priority 19-10-07 UK)	“Oral composition comprising a cooling agent”
	<b><u>18-10-2008</u></b>	
1233/3008	Abbott GmbH & Co. KG, Germany (Priority 19-10-07 USA)	“Solid dispersion product containing N- aryl urea-A-based compound”
1234/2008	Abbott Laboratories USA (Priority 19-10-2008 USA)	“Crystalline chemotherapeutic”
1235/2008	Abbott Laboratories USA (Priority 19-10-2007 USA)	“Crystalline chemotherapeutic”
1236/2008	Abbott Laboratories USA (Priority 19-10-2007 USA)	“Crystalline chemotherapeutic”
1237/2008	Abbott Laboratories USA (Priority 19-10-2007 USA)	“Crystalline chemotherapeutic”
1238/2008	Abbott Laboratories USA (Priority 19-10-2007 USA)	“Crystalline chemotherapeutic”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

113/1998	Glaxo Wellcome Australia Limited, Australia	“A pharmaceutical composition comprising fluticasone ester”  (A61K, 9/00, A61K, 31/56)	<b>139822</b>
----------	---	---	---------------

The present invention relates to a composition comprising fluticasone propionate substantially all having a particle size of less the 12 microns; one or more surfactants one or more buffer agents; and water.

1230/1998	Eli Lilly and Company, USA.	“A stable pharmaceutical composition comprising a teriparatide compound”  (A61K, 38/29)	<b>139823</b>
-----------	-----------------------------------	--	---------------

A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol, an acetate or Tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.

682/2000 Eli Lilly and Company, USA.

“A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride”

(C07D, 409/12)

**139824**

The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] -phenoxy) -2-(4methoxyphenyl)benzo[b] thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating chat.”


244/2004 Sanofi-Aventis Deutschland GmbH, Germany.

“A substituted azaindole compound”

(C07D, 471/04)

**139825**

The present invention relates to compound of the



wherein R<sup>0</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, Q, V, G and M have the meanings indicated in the claims. The compound of the formula I are valuable pharmacologically active compound. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor Vila (FVIIa), and can

in general be applied in condition in which an undesired activity of factor Xa and/or factor Vila is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. their use, in particular as active ingredient in pharmaceuticals.


249/2004 Wyeth,  
USA.

“A pharmaceutical composition comprising [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0] NON-1 (7)-EN-2-yl) alkyl]phosphonic acid”

(A61K, 31/662)

**139826**

Pharmaceutical composition for intranasal administration are provided that contain at least one compound of formula (I)



(I)

and one or more pharmaceutically acceptable additive for forming a composition for intranasal administration. Also provided are method of treating one or more conditions in a mammal associated with a glutamate abnormality that includes administering intranasally to a mammal a therapeutically effective amount of a compound of formula (I).

211/2005 The Gillette  
Company,  
USA.

“Shaving Razor”

(B26B, 21/22)

**139827**

A shaving razor blade unit including a housing having a primary guard at a front of the housing and a primary cap at an upper surface at a back of the housing, one or more primary shaving blades

between the primary guard and the primary cap, a rear wall having a rear exterior surface extending downward from the upper surface at the back of the housing to a terminating surface, and a trimming blade mounted on the rear wall and having a trimming cutting edge extending at least partially beyond the terminating surface inside of an imaginary extension of the rear exterior surface, the rear exterior surface defining a secondary cap for the trimming blade. The back of the housing can include trimming guard including spaced guard segments. The trimming blade, trimming guard and trimming cap can be provided as an assembly that is attached to the rest of the housing. The assembly can include a sheet metal support with a blade welded to the support.

361/2005 Fosroc  
International  
Limited,  
Great Britain.

“Sacrificial anode assembly”

(C23F, 13/06)

**139828**



A sacrificial anode assembly for cathodically protecting and/or passivating a metal section, comprising: (a) a cell, which has an anode and a cathode arranged so as to not be in electronic contact with each other but so as to be in ionic contact with each other such that current can flow between the anode and the cathode; (b) a connector attached to the anode of the cell for electrically connecting the anode to the metal section to be cathodically protected; and (c) a sacrificial anode electrically connected in series with the cathode of the cell; wherein the cell is otherwise isolated from the environment such that current can only flow into and out of the cell via the sacrificial anode and the connector. The invention also provides a method of cathodically protecting metal in which such a sacrificial anode assembly is cathodically attached to the metal via the connector of the assembly and a reinforced concrete structure wherein some or all of the reinforcement is cathodically protected by such a method.

The present invention provides method for industrial bleaching of a substrate by use of specific conditions and sequestrant, the method comprising subjecting the substrate in an aqueous medium, the aqueous medium comprising:

From 0.1 to 100 micromolar of a preformed transition metal catalyst; and

From 0.1 to 10 g/l of an aminocarboxylate sequestrant or alkali/alkaline metal salt thereof; and, from 5 to 1500 mM hydrogen peroxide,

Wherein the aqueous medium is buffered with a buffer selected from the group consisting a carbonate buffer having a pH in the range from 7,5 to 9.5 and a borate buffer having a pH in the range from 9 to 10.3 and wherein the preformed transition metal catalyst salt is a mononuclear or dinuclear complex of a Mn II-V transition metal catalyst, the ligand of the transition metal catalyst of formula (I):



P is 3;

R is independently selected from: hydrogen, C1-C6-alkyl, C2)H, C1COOH, and pyridine-2-ylmethyl or one of R is linked to the N of another Q via an ethylene bridge; R1, R2, R3, and R4 are independently selected from: H, C1-C4-alkyl, and C1-C4-alkylhydroxy.

41/2007

GCG Holdings  
Limited,  
Baganas.

“Stud with lengthwise indented ribs and method”  
(E04C, 3/09)

**139830**

A steel stud member for use in supporting structures and having reduced thickness as compared with conventional studs, and having a web having side edges, flanges on the side edges, formed at angles to the web, the web and the flanges enclosing inside surfaces, and having outside surfaces for mounting structure, and plurality of narrow indented longitudinal ribs formed in the flanges, and in the web, indented inwardly from the outside to the inside of the flanges, providing greater load bearing capacity for a given gauge of steel.

Also disclosed is a method of making such a steel member.

④④④④④④

## SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139473	Pfizer Inc., USA	652/1996
139474	Almirall Prodesfarma, S.A. Spain	754/1998
139475	Daiichi Pharmaceutical Co. Ltd., Japan	1014/1999
139476	AstraZeneca AB, Sweden	455/2000
139477	F. Hoffmann-La Roche AG., Switzerland	431/2001
139478	Janssen Pharmaceutica N.V. Belgium	568/2001
139479	Janssen Pharmaceutica N.V. Belgium	569/2001
139480	F. Hoffmann-La Roche AG., Switzerland	602/2001
139481	F. Hoffmann-La Roche AG., Switzerland	659/2001
139482	Sumitomo Chemical Company, Ltd. Japan	124/2003
139483	AstraZeneca AB, Sweden	729/2003
139484	F. Hoffmann-La Roche AG. Switzerland	763/2007

**(MRS. YASMEEN ABBASI)**  
CONTROLLER OF PATENTS  
Tel: 9215488